CYP3A4 and Hepatic failure: Nefazodone was withdrawn from the market because it was associated with hepatotoxicity and hepatic failure [85,86] owing to the actions exerted over the cytochrome P450 (CYP3A4) and the complex I of the mETC, which increase the formation of reactive oxygen species [44].